The Marin, Barrett, and Murphy Law Firm focusing on Zantac lawsuits on behalf of cancer victims
Have You Been Diagnosed with Cancer After Taking Zantac?



If you’ve used the popular heartburn drug Zantac or generic brands of the ranitidine product in the past, it’s important to know about the possible dangers of this over-the-counter drug. You may have heard in the news that Zantac, also known as ranitidine, has been linked to cancer. Nationwide, Zantac lawsuits against manufacturers allege the drug contains a cancer-causing chemical called N-nitrosodimethylamine NDMA. At Marin and Barrett, Inc., our top Zantac drug cancer lawyers are currently reviewing claims of individuals who took Zantac and later received a cancer diagnosis.

Recently, hundreds of Zantac Cancer Lawsuits have been filed involving former Zantac heartburn medication users who have received a cancer diagnosis following years of exposure to ranitidine. The Zantac law firms who have filed the existing federal Zantac lawsuits allege the defendants, pharmaceutical companies including Boehringer Ingelheim Pharmaceuticals, Sanofi, Chattem, Pfizer, and Glaxosmithkline, failed to disclose to consumers that the weight of scientific evidence showed Zantac exposed users to unsafe levels of NDMA and that they failed to report these cancer risks to the FDA. These federal Zantac lawsuits against the have been consolidated for purposes of discovery and other pre-trial aspects of the lawsuits in the U.S. District Court for the Southern District of Florida and are overseen by U.S. District Judge Robin L. Rosenberg.  It is anticipated that bellwether trials will commence in the fall of 2022 and into early 2023.


Approved by the United States Food and Drug Administration (FDA) in 1981, Zantac (ranitidine) was long considered to be a safe and effective treatment of gastro-esophageal reflux disease (GERD). In fact, the active ingredient in Zantac, ranitidine, has been used by hundreds of millions of people with heartburn, acid reflux, and gastric ulcer symptoms. It is estimated that over 120 million over-the-counter packages of Zantac have been sold annually in the United States alone.

However, recent studies have shown that persons taking Zantac or ranitidine are at a heightened risk of developing cancer. On September 26, 2019 the FDA announced the voluntary recall of over-the-counter ranitidine products labeled by Walmart, Walgreens, and Rite Aid that were produced by Apotex Corp. Then later, on April 1, 2020 the FDA released a statement requesting that manufacturers withdraw all prescription and over-the-counter (OTC) Zantac and ranitidine drugs from the market immediately.

The Latest Zantac Updates

May 8, 2024: Pfizer Agrees to Settle Over 10,000 Zantac Lawsuits

In a significant development for individuals affected by Zantac, Pfizer Inc. has agreed to settle more than 10,000 lawsuits related to the cancer risks associated with the drug. This settlement covers cases in U.S. state courts but does not entirely resolve Pfizer’s potential liabilities. For those who have already filed claims, this settlement represents a crucial step towards receiving compensation for their injuries linked to the presence of NDMA, a known carcinogen, in Zantac.

For individuals who have not yet filed a claim, this news highlights the urgency of taking legal action. As settlements continue to be reached, there is a risk that a global settlement could be finalized, potentially barring new claims. Those who believe they have been harmed by Zantac should seek legal advice promptly to ensure their rights are protected and to secure their chance for compensation before it’s too late.

This development emphasizes the importance for all potential claimants to act quickly. The ongoing legal proceedings and settlements are shaping the landscape of Zantac litigation, and those who delay may miss their opportunity to be included in any future compensation agreements. Legal counsel can provide guidance on the necessary steps to take to file a claim and participate in potential settlements.

May 1, 2024: Historic First Trial Over Zantac Cancer Claims Commences in Chicago

This week marks a pivotal moment for individuals impacted by Zantac, as the first trial addressing cancer claims related to the drug begins in Chicago’s Circuit Court of Cook County. The trial, involving plaintiff Angela Valadez, an 89-year-old Illinois resident, focuses on allegations that her long-term use of over-the-counter Zantac and its generic counterparts led to her developing colorectal cancer. This case will test the claims that the active ingredient in Zantac, ranitidine, can transform into the carcinogen NDMA as it ages.

The outcomes of this trial could set a significant precedent for tens of thousands of similar lawsuits against major pharmaceutical companies like GSK and Boehringer Ingelheim, which are the primary defendants in this landmark case.

This trial not only represents a test of the legal claims against Zantac but also a critical moment for accountability in the pharmaceutical industry. As such, it is imperative for individuals who believe they have been harmed by Zantac to seek legal advice and consider their options. The proceedings in Chicago could potentially influence the landscape of pharmaceutical litigation and encourage other claimants to pursue their rights to compensation.

April 29, 2024: Urgent Call for Zantac Users as Sanofi Agrees to $100 Million Settlement

In a significant development for those affected by Zantac, Sanofi has agreed to a $100 million settlement to resolve claims from approximately 4,000 plaintiffs. Each claimant is set to receive about $25,000, addressing allegations that Zantac, once containing the ingredient ranitidine, could cause cancer. This agreement follows numerous lawsuits asserting that Sanofi failed to adequately warn users about the potential carcinogenic risks of Zantac.

While Sanofi continues to deny that Zantac causes cancer, aligning with a 2022 court ruling that dismissed federal claims due to insufficient evidence, this settlement sends a powerful message. It highlights the potential for claimants to receive compensation, despite ongoing disputes over scientific proofs and legal liabilities. This resolution not only provides relief to thousands but also establishes a precedent for financial recovery for individuals harmed by Zantac.

For users diagnosed with cancer linked to Zantac, the time to act is now. This settlement may influence the outcomes of approximately 75,000 pending cases consolidated in Delaware, possibly paving the way for more substantial settlements. It’s crucial for those affected to come forward and secure their rights to compensation before other settlements are reached.

April 4, 2024: Sanofi to settle 4,000 Zantac cancer lawsuits in U.S. state courts

In a landmark development, Sanofi has agreed in principle to settle around 4,000 lawsuits across the United States, where plaintiffs allege the company’s heartburn medication, Zantac, is linked to cancer. This move marks a pivotal moment in the ongoing legal saga, addressing a significant fraction of the lawsuits in state courts outside of Delaware, where the majority of cases are still under consideration.

This settlement is a crucial reminder for individuals who have used Zantac and may have developed cancer as a result, highlighting the urgency of bringing forward claims before it’s too late. As Sanofi faces approximately 20,000 additional lawsuits in Delaware alone, the outcome of these proceedings could set significant precedents. The litigation landscape for Zantac claims is rapidly evolving, with a judge in the Delaware Superior Court poised to influence the direction of nearly 70,000 claims against various defendants, including GSK, Pfizer, and Boehringer Ingelheim. This juncture serves as a critical call to action for potential claimants to seek legal advice and file their claims promptly, ensuring they are included in any future settlements or court decisions.

February 29, 2024: GSK Reaches Another Settlement in Zantac Litigation in California

GlaxoSmithKline (GSK) has once again avoided trial with a settlement in a California lawsuit concerning its heartburn medication, Zantac (ranitidine). This marks the second settlement in California within a span of four weeks, highlighting the pharmaceutical giant’s strategy to handle the ongoing legal challenges surrounding Zantac without admitting any liability. The settlement details remain confidential, but GSK’s official statement emphasizes their intent to prevent the distractions associated with prolonged court proceedings. The case, which was set for trial on April 2, is now dismissed following this agreement.

This recent settlement follows closely on the heels of another case resolved earlier this month, involving plaintiff David Browne, which was scheduled for a February 20 trial. These legal actions are part of a broader litigation landscape that emerged after 2019 when concerns were raised about Zantac’s active ingredient, ranitidine, potentially converting into N-nitrosodimethylamine (NDMA), a substance known to cause cancer. The scrutiny intensified after an online pharmacy detected high levels of NDMA in Zantac and its generic counterparts, leading to recalls and the eventual FDA mandate to remove Zantac from the market.

The legal trajectory of Zantac has been fraught with challenges for GSK and other associated manufacturers, facing thousands of claims alleging that long-term use of ranitidine led to various cancers. Despite these settlements, GSK maintains a stance of vigorous defense based on scientific evidence and facts for all remaining Zantac cases. These developments are crucial for individuals following the Zantac litigation and for stakeholders in the pharmaceutical industry, signaling a continued effort to address and resolve these claims outside the courtroom.

October 11, 2023:  GlaxoSmithKline (GSK) plc, a prominent British pharmaceutical company, has announced the settlement of another lawsuit alleging that its discontinued heartburn medication Zantac can cause cancer. The settlement pertains to the Cantlay/Harper case in California, with GSK reaching a confidential agreement before the trial, scheduled for November 13. While the financial terms remain undisclosed, this development marks a significant turn in the ongoing legal battle surrounding Zantac.

In a parallel announcement, GSK confirmed the settlement of three additional cases in California, all linked to breast cancer claims related to Zantac. These settlements lead to the dismissal of these four cases, coinciding with the FDA’s strong recommendation for the immediate removal of Zantac from the market due to cancer risks.

The legal landscape for GSK is extensive, with approximately 3,100 claims filed in California and over 73,000 in Delaware. A crucial hearing in January will determine the future course of the Delaware cases.

April 13, 2023: A California judge has allowed a lawsuit against GlaxoSmithKline (GSK) to proceed, linking Zantac to several types of cancer. The ruling comes despite a dismissal of around 50,000 federal Zantac claims by Judge Robin Rosenberg in December 2022. GSK argues that there is no convincing evidence that the drug’s main ingredient, ranitidine, causes cancer. However, Zantac was pulled from the market in 2020 after tests showed that ranitidine could transform into a potentially carcinogenic compound, N-Nitrosodimethylamine (NDMA), when stored at above room temperature for a long time.

October 18, 2022: While a federal judge continues to oversee the Daubert hearings this week, the plaintiff filed an expedited motion, requesting permission to file a supplemental report. As reported by Law360, it includes data from a recently published study suggesting ranitidine, the H2-blocking drug known by its brand name Zantac, may cause four types of cancer. If the judge allows the new report, five expert witnesses would be allowed to file supplemental reports in Daubert hearings, which weigh admissibility of evidence in pretrial proceedings.The study, published Sept. 30 in the International Journal of Environmental Research and Public Health, links ranitidine to an increased risk of lung, liver, pancreatic and stomach cancer.
September 26, 2022: The Daubert hearings began last week and will continue into this week. Daubert hearings occur in almost every major medical malpractice lawsuit with an expert witness(s). The hearings permit the parties to examine the challenged expert in open court to develop his or her testimony for purposes of evaluating its admissibility. A trial judge serves as the gatekeeper who determines whether an expert’s evidence is deemed reputable and relevant. The direction of the Daubert hearings will greatly impact the direction of the Zantac trial.  
September 7, 2022: This week, two major investment banks announced that they have cut their target prices of GSK PLC (the pharmaceutical company that manufactured and sold Zantac). Both Morgan Stanley and Deutsche Bank announced they were cutting the price target after analysts finally began digging into the legal claims of those that have been diagnosed with cancer after using the heartburn medication. It seems like the analysts, like the attorneys pursuing these claims, believe that the science linking the Zantac to a number of different types of cancers is extremely strong and will lead to a large plaintiff’s verdicts in the upcoming bellwether trials in early 2023.  
August 17, 2022: This week, three Zantac manufacturers agreed to pay $500,000 this week to settle a Zantac cancer lawsuit that was set to go to trial in Illinois state court.
The plaintiff, Joseph Bayer, is suffering from esophageal cancer and agreed to drop his claims due to health reasons. His Zantac complaint had blamed the Zantac manufacturers for his esophageal cancer, based on taking NDMA contaminated over-the-counter Zantac product for years. While the settlement allows the defendants to avoid what would be the first Zantac cancer trial, the fact that the Defendant manufacturers were willing to pay $500,0000 to avoid trial is a positive sign for other plaintiffs going to trial in the upcoming Zantac MDL bellwether trials in Federal Court and a positive development for future settlement negotiations.
August 13, 2022: With the bellwether trials on the horizon, many big pharmacy companies with connections to Zantac, reported significant drops in stock value. The sell-off is an indication that Wall Street is extremely concerned with the upcoming trials and that the payout per person in this personal injury lawsuit may be massive.

May – August 17, 2022:While certain state trials start as early as October, other federal trials will be in early 2023. In the background, both plaintiffs and defendant lawyers are working around the clock preparing a variety of different discovery materials and motions along with the judge overseeing the trials prior to their start to set the direction of each individual trial.
April 2022: Zantac cancer lawsuits in the MDL reach 2,100 plaintiffs. The anticipated real number though is much higher, as many lawsuits have started to get dismissed due to the fact that the judge has narrowed it down to only one type of five cancers.

Zantac Cancer Attorney

If you or a loved one have been diagnosed with cancer after using Zantac or ranitidine, call the Zantac Attorneys at the Marin, Barrett, and Murphy Law Firm today at 888-348-2735 for a free, no obligation consultation. We can help you take legal action and commence with your Zantac lawsuit to secure financial compensation.


Following reports of elevated levels of NDMA in ranitidine medicines to the FDA in June 2019, testing revealed that levels of NDMA in ranitidine actually increased over time if stored at room temperature. Since the summer of 2019, additional testing has shown that exposing ranitidine to high temperatures can lead to even greater increases in NDMA. the World Health Organization and the US Environmental Protection Agency (EPA) classify NDMA as a “probable human carcinogen.”

The FDA found that the older the age of the ranitidine product, or the longer the length of time since it was manufactured, the greater the level of NDMA. Factor in the correlation between storage temperature and manufacture date of any given individual’s Zantac supply, the levels of NDMA may eventually exceed acceptable daily intake limits.

Though research into the long-term consequences of ingestion or consumption of toxic carcinogens such as NDMA and NDEA is ongoing, the preliminary results are certainly concerning and show an increased risk of cancer.

package of Zantac

Studies have shown close links between the usage of Zantac and medical conditions such as colon cancer, liver cancer, cancer of the uterus, rectal cancer, stomach cancer, intestinal cancer, thyroid cancer, kidney cancer, esophageal cancer, pancreatic cancer, and bladder cancer. Additional studies have also shown that unacceptable levels of NDMA could cause non-cancerous liver damage, internal bleeding, and death.

There has been a recent groundswell of lawsuits filed nationwide claiming that manufacturers of Zantac, such as GlaxoSmithKline, Boehringer Ingelheim, Johnson & Johnson, Pfizer, and Sanofi, knew about the levels of NDMA within ranitidine and the risks of cancer associated with the use of their products, yet failed to inform the public. Until as recently as March 30, 2020, Zantac was still readily available for sale with minimal warning of the risk of using the drug. Here at the Marin, Barrett, and Murphy Law Firm, a Zantac Cancer Lawsuit Lawyer can help those injured and sickened by Zantac obtain compensation.

What Should You Do If You Took Zantac?

If you or a loved one believe that you have been or are currently taking Zantac seeking medical attention should be your first priority. The FDA advises you not to discontinue your medication until receiving a replacement or alternative from your doctor, pharmacist, or healthcare provider. Stopping medication abruptly and without professional guidance can lead to immediate and severe health complications. Your doctor or pharmacist may be able to advise an alternative treatment or provide medication that has not been contaminated. You can search the FDA list of recalled medications; you should be able to find the drug manufacturer and lot number on the prescription bottle or the warning label. If you are unable to do so, ask your pharmacist for assistance.

In the event that you or a loved one has suffered complications after taking Zantac we stand ready to help you take legal action. We are committed to holding the responsible parties accountable and getting you the compensation you deserve. Call the Zantac Attorneys at the Marin, Barrett, and Murphy Law Firm at 888-348-2735 today, the consultation is confidential and of absolutely no cost to you.


In light of the recent recall of medications that contain ranitidine, at least a hundred injured plaintiffs across the country have filed Zantac lawsuits and ranitidine lawsuits seeking compensation for their medical bills, lost wages, pain and suffering and, in the most unfortunate cases, funeral expenses. Manufacturers of Zantac such as Sanofi, Boehringer Ingelheim, Johnson & Johnson, and Pfizer knew or should have known that the active ingredient, ranitidine, contained dangerous levels of the cancer-causing carcinogen, NDMA. Many of these lawsuits allege that the manufacturers knew of the potential harm the NDMA-associated dangers posed to consumers by these products and actively concealed the dangers from the public.

As a result of the number of persons injured by taking Zantac coming forward (and the corresponding Zantac lawsuits against the drug manufacturers), the United States Judicial Panel on Multidistrict Litigation (“MDL”) consolidated the Zantac lawsuits in the Southern District of Florida under U.S. District Judge Robin Rosenberg. The job of the panel on the MDL is to determine whether civil actions pending in different federal districts involve one or more common questions of fact such that the actions should be transferred to one federal district for coordinated or consolidated pretrial proceedings; and to select a judge or judges and court assigned to conduct such proceedings.

Plaintiffs in California, New Jersey, New York, Ohio, and Tennessee have filed Zantac lawsuits against manufacturers of Zantac in their respective jurisdictions, but the MDL determined that the Southern District of Florida was the most appropriate venue for consolidation given that the majority of those injured after using Zantac live there. In the transfer order, the panel said the Zantac cases “could be a large litigation.” As of February 2020, there were over 140 pending Zantac lawsuits, although that number is expected to climb in the coming months and years.

Unfortunately, as the case has unfolded many of the initial claims have been removed from the Zantac MDL.  In 2021, the Judge in the Zantac mulit-district litigation dismissed the legal claims brought against the makers of generic ranitidine products and the retail stores that sold Zantac products including CVS and Rite Aid.  This meant that those individuals who took the generic versions of Zantac, known as Ranitidine, would not be able to pursue their personal injury claims.

Then, in 2022 the Plaintiffs revealed that their expert witnesses could not establish a link between Zantac and a number of cancers including brain cancer, testicular cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer, and lung cancer.  This severely limited the forms of cancer that were eligible to continue pursuing a cancer claim.

Unlike class action lawsuits, the Zantac lawsuits that have been consolidated in the Federal Courts as part of the multi-district litigation (MDL) process are mass tort cases.  The Zantac MDL allows Zantac claims to use a streamlined discovery process while offering the Zantac claimant the ability to later return their claim to their local Federal District Court for a Zantac trial.  The Zantac MDL cannot force a Zantac settlement on all the other members of the Zantac MDL the way a traditional class action lawsuit can.

With so many instances of individuals unknowingly taking products tainted with NDMA coupled with the unwillingness of the Zantac manufacturers to take responsibility to warn the public, it is likely that more Zantac users will realize that they were seriously harmed by the product. If you or a loved one has become injured or ill after using Zantac, do not hesitate to call the dangerous drug attorneys at the Marin, Barrett, and Murphy Law Firm at 888-348-2735 today, the consultation is confidential and of absolutely no cost to you.


If you or a loved one has developed cancer or other complications from using Zantac call us today. We will examine you case for free to help you determine if you have a claim. The call, consultation, and information are no-obligation and completely confidential. We work with and among some of the most regarded professionals in the industry all in the interest of getting you everything you deserve for your damages.

At the Marin, Barrett, and Murphy Law Firm we believe in a fully transparent fee structure. We work on a strictly contingency fee basis, meaning that we do not receive anything from you unless we are able to recover money either by a Zantac settlement or Zantac verdict. Regardless of what type of case you have or what is required, you will know everything up front with no surprises. We shoulder the costs of the filing and Zantac litigation on your behalf and at no risk to you.

Call us today at 888-348-2735 to schedule your free consultation with our local Rhode Island or Connecticut Zantac cancer lawsuit attorneys, it only takes a few moments and there is never any obligation.


Prescription ranitidine and Zantac OTC are used for treatment and prevention of stomach ulcers, intestinal ulcers, heartburn, and treatment of gastroesophageal reflux disease. These medicines are known as H2 (histamine-2) blockers and work by decreasing the amount of acid created by the stomach thereby alleviating discomfort associated with digestive disorders. Ranitidine is typically ingested by tablet, liquid, or capsule form in the morning and in the evening (or before the first and last meal of the day). If you are currently taking Zantac or have recently, you should contact your prescribing doctor or primary care physician immediately. Recent laboratory tests conducted by the FDA have shown that the active ingredient in Zantac and ranitidine puts people more at risk to developing certain types of cancer.

The FDA has determined people should consume no more than 96 nanograms of NDMA a day. Recent lab testing found some Zantac formulas contain more than 3,000,000 ng per tablet.



In September 2019, the FDA discovered through independent laboratory test results that some ranitidine medications such as Zantac contained N-nitrosodimethylamine (NDMA) at low levels. NDMA is classified as a probable human cancer-causing carcinogen. The FDA, however, did not issue a recall at that time for ranitidine because the NDMA levels were deemed low enough that it “would not be expected to lead to an increase in risk in cancer”. Instead, the FDA issued a warning to the public that there were potential risks to using ranitidine medications and urged the public to consider alternative over-the-counter and prescription treatments.

It was not until April 1, 2020 that the FDA actually issued a formal recall of products containing ranitidine. Because the initial FDA warning in 2019 did not require the manufacturers to take the products out of circulation, drugs such as Zantac stayed on the market notwithstanding the fact that they had been shown to contain the cancer-causing carcinogen NDMA.


  • Zantac 150
  • Zantac 150 Maximum Strength
  • Zantac Maximum Strength Cool Mint
  • Zantac 75
  • Wal-Zan 150
  • Wal-Zan 75
  • Heartburn Relief
  • Acid Reducer
  • Acid Control


NDMA is an environmental contaminant that is found in water and foods, including dairy products, vegetables, and grilled meats. Its classification as a probable carcinogen is based on studies in animals; studies in humans are very limited. According to a 2008 report published by the World Health Organization, NDMA can occur in drinking-water through the degradation of dimethylhydrazine, a component of rocket fuel, as well as from several other industrial processes. ​ There is conclusive evidence that NDMA is a potent carcinogen. This has been demonstrated through experiments exposing animals to NDMA through several ways, including through ingestion of drinking-water.

As a consequence of the clear evidence of carcinogenicity, there have been few studies of other possible toxic end-points, and even fewer studies of tests on humans due to the demonstrable evidence of carcinogenicity.​

It is important to note that although carcinogenic, the FDA has determined that NDMA in small amounts is acceptable. According to the FDA, consuming up to 0.096 micrograms or 0.32 parts per million (ppm) of NDMA per day is considered reasonably safe for human ingestion based on lifetime exposure. FDA has set the acceptable daily intake limit for NDMA at 0.096 micrograms or 0.32 ppm for ranitidine. However, a recent test of ranitidine conducted by Valisure, a pharmacy/laboratory based in Connecticut, showed that one 150 mg tablet of Zantac produced 3 milligrams of NDMA, 1,700 times the exposure level found to be carcinogenic in some studies. These findings were reported to the FDA in June 2019 and ultimately led to the FDA issuing an announcement that ranitidine medicines, including Zantac, contained NDMA, the cancer-causing carcinogen.


If you took Zantac and have been diagnosed with cancer, our attorneys will be seeking the following damages for you:

  • Past and future medical expenses that result from your diagnosis and treatment
  • Past and future pain and suffering (physical and mental) caused by your diagnosis, treatment, and the recovery process
  • Past and future wage loss
  • Past and future loss of earning capacity
  • Past and future loss of enjoyment of life
  • Punitive damages to deter drug companies from selling harmful products in the future


At this time, there have been no settlements or jury verdicts involving Zantac and its cancer causing properties. In February 2020, Multidistrict Litigation ordered that all Zantac cases be centralized and consolidated in the U.S. District Court for the Southern District of Florida where the litigation will be overseen by U.S. District Judge Robin L. Rosenburg during coordinated discovery and pre-trial proceedings.


If you or a loved one has developed colon cancer, liver cancer, cancer of the uterus, rectal cancer, stomach cancer, kidney cancer, esophageal cancer, pancreatic cancer, or bladder cancer and believe that use of Zantac may be responsible call us today. We will examine you case for free and at no obligation to you and help you determine whether you have a claim. The call, consultation, and information are no-obligation and completely confidential. Our Zantac cancer law firm works with and among some of the most regarded legal professionals in the industry all in the interest of getting you everything you deserve.

At the Marin, Barrett, and Murphy Law Firm we believe is a fully transparent fee structure. We work on a strictly contingency fee basis, meaning that we do not receive anything from you unless we are able to recover money either by settlement or verdict. Regardless of what type of case you have or what is required, you will know everything up front with no surprises. We shoulder the costs of the filing and litigation on your behalf and at no risk to you. A top rated Zantac cancer lawyer can help you bring an individual lawsuit against the drug company that produced the defective drugs that harmed you to cover your medical costs. If you used the over-the-counter medication, you can show prior use through receipts, notes in your medical record, or even through witnesses who live with you and can testify to your regular use of the drug.

Contact our team of Zantac personal injury lawyers at the Marin, Barrett, and Murphy Law Firm today at 888-348-2735 to schedule your free consultation, it only takes a few moments and there is no obligation.  We have a personal injury attorney standing by to discuss your claim with you.


Disclaimer: Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Past results afford no guarantee of future results and each case is different and is judged on its own merits. Some cases result in no recovery. Costs and expenses will be advanced and reimbursed to us only if you recover. You have no liability for costs or expenses unless a court directs. The choice of a lawyer is an important decision and should not be based solely upon advertisements. Some matters may be referred to other lawyers. From the Marin, Barrett and Murphy Law Firm’s offices in Rhode Island the firm has represented clients from all parts of Rhode Island, Connecticut, and Massachusetts and has partnered with other law firms to serve clients throughout the U.S.


Admitted in Rhode Island, Connecticut, Massachusetts and South Carolina​


Admitted in Rhode Island